Hologic is positioning its Genius AI-driven software within the fast-growing point-of-care diagnostics market, which analysts project will reach $70.92 billion by 2032. As the CMS ACCESS Model launches in July 2026 to reward outcome-based imaging, Hologic’s software-defined platforms aim to deliver hospital-grade MRI precision at the bedside. The company is collaborating with partners such as VentriPoint Diagnostics and GE HealthCare to integrate its advanced image-reconstruction algorithms into portable ultrasound and MRI systems, reducing facility overhead by up to 30% while maintaining sub-millimeter spatial resolution.

Hologic has rolled out the Ultimate Defense initiative, a nationwide U.S. campaign urging routine Pap and HPV testing. The program targets a 15% increase in annual screening rates among women aged 21–65, addressing current underscreening trends that have seen participation drop below 70%. Ultimate Defense deploys digital outreach, community health partnerships and mobile screening units in 12 metropolitan areas, with success metrics tracked through quarterly public health reports and hospital network data sharing agreements.

Hologic will release its first quarter fiscal 2026 results on Thursday, January 29, after market close, foregoing a traditional earnings call and guidance in light of its pending acquisition by Blackstone and TPG. Investors will monitor revenue contributions from the Diagnostics division, which grew 18% year-over-year in the prior quarter, and the Breast Health segment, where digital biopsy devices accounted for over 40% of unit volumes. Management has indicated that integration costs related to the acquisition will be disclosed in the 10-Q filing.